Commentary

Case study - the merits of adaptive trial design

Read more

Ipsen aspires to role as speciality oncology player

Read more

New body for regenerative medicine launched

Read more

Why patient-reported outcomes matter

Read more

Is an EU approval better than a hospital exemption?

Read more

The Trump impact on healthcare M&A

Read more

Protein scaffolds - coming of age as therapies

Read more

Cheap capital gives rise to integrated pharma R&D

Read more

Commentary: Thought disruption in R&D discovery

Read more

Market Analysis: The outlook for European pharma

Read more